<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03688490</url>
  </required_header>
  <id_info>
    <org_study_id>PASYMPLE</org_study_id>
    <nct_id>NCT03688490</nct_id>
  </id_info>
  <brief_title>Clinical Characteristics of Aquagenic Pruritus in Patients With Myeloproliferative Neoplasms</brief_title>
  <acronym>PASYMPLE</acronym>
  <official_title>Aquagenic Pruritus Among Patients With Myeloproliferative Syndromes (in English) Prurit Aquagénique Dans Les SYndromes MyéloProLifEratifs (in French)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Description of the characteristics of aquagenic pruritus expressed by patients suffering from
      myeloproliferative neoplasms.

      Prospective work based on the distribution of a dedicated questionnaire.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with myeloproliferative neoplasms identified and followed in our Institution (Brest
      University Hospital). Patients could be followed for polycythemia vera or essential
      thrombocythemia or myelofibrosis.

      Distribution of the questionnaire to each patients with myeloproliferative neoplasms (treated
      or not) suffering from aquagenic pruritus.

      Analyse of each characteristic of the aquagenic pruritus by a statistician and publication at
      the end.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 17, 2013</start_date>
  <completion_date type="Actual">November 4, 2013</completion_date>
  <primary_completion_date type="Actual">November 4, 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Intensity of the pruritus</measure>
    <time_frame>15 days</time_frame>
    <description>Analogic Visual Scale, from 0 to 10, Worse if &gt;6</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of the pruritus</measure>
    <time_frame>15 days</time_frame>
    <description>Timing expresses in minutes</description>
  </secondary_outcome>
  <enrollment type="Actual">70</enrollment>
  <condition>Myeloproliferative Disorder</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients followed for myeloproliferative neoplasms in our Institution (Brest University
        Hospital)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients followed with myeloproliferative neoplasms

          -  suffering from aquagenic pruritus

        Exclusion Criteria:

          -  Unable to fulfil the questionnaire

          -  No written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>IANOTTO Jean-Christophe, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hématologie Clinique-Institut de Cancéro-Hématologie</affiliation>
  </overall_official>
  <results_reference>
    <citation>Le Gall-Ianotto C, Brenaut E, Gouillou M, Lacut K, Nowak E, Tempescul A, Berthou C, Ugo V, Carré JL, Misery L, Ianotto JC. Clinical characteristics of aquagenic pruritus in patients with myeloproliferative neoplasms. Br J Dermatol. 2017 Jan;176(1):255-258. doi: 10.1111/bjd.14809. Epub 2016 Dec 22.</citation>
    <PMID>27291777</PMID>
  </results_reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>September 20, 2018</study_first_submitted>
  <study_first_submitted_qc>September 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2018</study_first_posted>
  <last_update_submitted>June 27, 2019</last_update_submitted>
  <last_update_submitted_qc>June 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aquagenic pruritus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

